Gain Therapeutics (GANX) Total Current Liabilities (2020 - 2026)

Gain Therapeutics has reported Total Current Liabilities for 7 years, with the latest figure at $3.4 million in Q2 2026.

• On a quarterly basis, Total Current Liabilities fell 33.93% year-over-year to $3.4 million in Q2 2026; TTM through Jun 2026 was $3.4 million, a 33.93% decrease from a year earlier, with the FY2025 full-year figure at $3.4 million, down 14.29% from the prior year.
• Total Current Liabilities was $3.4 million for Q2 2026 at Gain Therapeutics, down from $3.9 million in the prior quarter.
• The five-year high for Total Current Liabilities was $6.5 million in Q2 2024, with the low at $3.4 million in Q4 2025.
• Average Total Current Liabilities over 5 years is $4.6 million, with a median of $4.5 million recorded in 2022.
• The sharpest annual moves came in 2022 and 2026: Total Current Liabilities jumped 81.24% in 2022, then plunged 33.93% in 2026.
• Over 5 years, Total Current Liabilities stood at $4.1 million in 2022, then increased by 19.99% to $4.9 million in 2023, then slipped by 20.98% to $3.9 million in 2024, then fell by 14.29% to $3.4 million in 2025, then grew by 2.43% to $3.4 million in 2026.
• The last three Total Current Liabilities figures came in at $3.4 million (Q2 2026), $3.9 million (Q1 2026), and $3.4 million (Q4 2025), per Business Quant data.